Variantyx

#ACMG25 is winding down, but it’s not over yet! Don’t leave the exhibit floor without stopping by booth 323 to learn about how we’re combining short and long-read WGS to enhance repeat expansion disorder diagnostics. Stop by to speak with Lucy Kaplun, author of our new publication, and dive into the details of our research! Learn more ?? https://ow.ly/21YW50Vmg3G

The doors are open, and we’re ready to connect! Stop by booth 626 to discover how “We See More” in every genome—delivering answers where others can’t. Explore our cutting-edge whole genome testing solutions Get excited for Dr. Christine Stanley’s Theater Talk today—featuring real cases where whole genome analysis made the difference Meet our team and see how we’re transforming rare disease diagnostics Let’s make this an unforgettable conference! See you at #ACMG2025! #Variantyx #WeSeeMore #WholeGenomeTesting #Genomics #RareDisease

At Variantyx, we’re always striving to see more and provide the most detailed insights into every patient’s genome. That’s why we incorporate long-read sequencing alongside our short-read technology. Long-read sequencing generates longer, more continuous sequences, making it easier to analyze complex genomic regions with precision. This addition enables us to: ?? Better characterize and identify repeat expansions ?? Better characterize and identify structural variants of all sizes ?? Analyze methylation patterns ?? Provide variant phasing for clearer understanding By combining short-read and long-read sequencing, we ensure that no detail is missed, delivering the most comprehensive genomic analysis possible. https://ow.ly/Lbwy50VjrQr #LongReadSequencing #GenomicInnovation #Healthcare #ChooseWisely #ChooseGenome #ChooseVariantyx #WeSeeMore #Variantyx

At Variantyx, we’re not just sequencing the genome—we’re revolutionizing how we analyze it. Long-read sequencing adds an extra dimension to genetic testing, making it possible to detect previously hidden variants with unmatched precision. ?? The Power of Long-Read Sequencing: ?? Enables better characterization of repeat expansions across 44 genes ?? Provides higher accuracy for detecting complex structural variants ?? Allows for methylation pattern analysis, giving deeper insights into genetic disorders By combining short-read and long-read sequencing, we provide the most complete and detailed genomic insights available today. This approach ensures that every genetic variation is accounted for, leading to more precise diagnoses and better patient care. https://ow.ly/t9FW50VjmtA #LongReadSequencing #GenomicInnovation #WholeGenomeTesting #WeSeeMore #Variantyx #ChooseWisely #GeneticTesting

Two Days to #ACMG2025 – Are You Ready? We’re counting down the days until #ACMG2025 kicks off, and we can’t wait to connect with you! Visit booth 626 to see how “We See More” in every genome—finding answers where others can’t. Don’t miss Dr. Christine Stanley’s Theater Talk on March 20, where she’ll present real-world cases where whole genome testing made the difference. Meet our experts and explore how comprehensive genomic analysis is shaping the future of rare disease diagnostics. The future of genetics starts here. See you in just two days! #Variantyx #WeSeeMore #WholeGenomeTesting #Genomics #RareDisease #ACMG

At Variantyx, we take whole genome analysis to the next level, ensuring no genetic detail is missed. Our approach provides the most complete picture of a patient’s genome, detecting all major variant types in a single test. Why our Whole Genome Analysis stands out: ?? Small sequence changes ?? ? Structural variants (copy number variants, duplications/deletions, regions of homozygosity, mobile element insertions, inversions, and aneuploidy.) ?? Mitochondrial genome analysis ?? Repeat expansions in 37 genes Learn more ?? https://ow.ly/keoo50ViLs3 #WholeGenomeAnalysis #GeneticTesting #PrecisionMedicine #WeSeeMore #Variantyx #HealthcareInnovation #GenomicExcellence #ChooseWisely #ChooseGenome

At Variantyx, we're constantly evolving to provide the most comprehensive and clinically relevant insights. We’re excited to announce the addition of the C9orf72 gene to our Genomic Unity? Movement Disorders Analysis! C9orf72 is one of the most common genetic causes of ALS (Amyotrophic Lateral Sclerosis) and FTD (Frontotemporal Dementia). With the ability to detect repeat expansions in this critical gene, we’re taking movement disorder analysis to the next level—providing deeper, more precise answers for patients and clinicians. Because every repeat expansion matters when diagnosing and treating movement disorders. We see more. #GenomicUnity #C9orf72 #MovementDisorders #GeneticTesting #Neurology #ALS #FTD #WeSeeMore #PrecisionMedicine #ChooseWisely

As healthcare providers we know that choosing the right genetic test can be one of the most important decisions in patient care. At Variantyx, we’re proud to offer the most comprehensive testing solutions, including combining short-read and long-read sequencing to provide the clearest, most detailed insights into the genome. Whether it detects repeat expansions, structural variants, or methylation patterns, our testing helps you make informed decisions – because when it comes to genetics, every detail matters. Choose wisely. Choose a test that provides the most in-depth answers for your patients. Stay tuned as we dive into the power of Genomic Unity? 2.0, and why it's the next step in comprehensive genomic testing. ?? https://ow.ly/N7Pf50Vhrb5 #ChooseWisely #ChooseGenome #ChooseVariantyx #WeSeeMore

Around age 30, our patient began experiencing gait and balance issues which progressed to chorea. Short and long term memory issues developed. Multiple repeat expansion genes tested negative. Four long years later, Variantyx whole genome testing identified the hidden variant. What was it? To find out, join Dr. Christine Stanley March 20 in the #ACMG2025 exhibit theater. You’ll see firsthand how We See More in every genome – delivering answers where others can’t. Visit us at booth 626 to learn more. #Variantyx #WeSeeMore #WholeGenomeTesting

The countdown begins! We’re thrilled to be exhibiting at #ACMG2025 from March 19-21 in Los Angeles! Stop by our booth (626) to explore how short and long-read whole genome analysis is revolutionizing diagnostics. Plus, don’t miss our exclusive Exhibit Theater Talk on March 20, where Dr. Christine Stanley will present how We See More in every genome – leading to deeper insights and better answers for patients. Stay tuned! #ACMG2025 #Variantyx #WeSeeMore